

Accepted Manuscript


Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Nobuya Inagaki, Wayne H.-H. Sheu, David R. Owens, Susanne Crowe, Amit Bhandari, Yan Gong, Sanjay Patel

PII: S1056-8727(16)30281-1
DOI: doi: [10.1016/j.jdiacomp.2016.07.002](https://doi.org/10.1016/j.jdiacomp.2016.07.002)
Reference: JDC 6790

To appear in: *Journal of Diabetes and Its Complications*

Received date: 18 February 2016
Revised date: 8 July 2016
Accepted date: 9 July 2016



Please cite this article as: Inagaki, N., Sheu, W.H.-H., Owens, D.R., Crowe, S., Bhandari, A., Gong, Y. & Patel, S., Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials, *Journal of Diabetes and Its Complications* (2016), doi: [10.1016/j.jdiacomp.2016.07.002](https://doi.org/10.1016/j.jdiacomp.2016.07.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Nobuya Inagaki^{a,*}, Wayne H.-H. Sheu^b, David R. Owens^c, Susanne Crowe^d,
Amit Bhandari^e, Yan Gong^d, Sanjay Patel^{f,†}

^a*Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan*

^b*Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan*

^c*Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, Wales, UK*

^d*Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany*

^e*Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA*

^f*Boehringer Ingelheim Ltd, Bracknell, UK[†]*

*Corresponding author: Professor Nobuya Inagaki, Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel.: +81-75-751-3562; fax: +81-75-771-6601.

E-mail address: inagaki@kuhp.kyoto-u.ac.jp

[†]Present address: Daiichi Sankyo Developments Ltd, Gerrards Cross, Buckinghamshire, UK

Download English Version:

<https://daneshyari.com/en/article/5901917>

Download Persian Version:

<https://daneshyari.com/article/5901917>

[Daneshyari.com](https://daneshyari.com)